Added to YB: 2025-12-02
Pitch date: 2025-11-28
NOVO-B.CO [neutral]
Novo Nordisk A/S
-2.44%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 315.10
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
value
Show full summary:
Theodosian Capital | Stocks Update 28/11/2025 - NOVOB – Go Evoke, go broke
NOVO-B.CO (update): Evoke Alzheimer's drug failed Phase III trials, missing statistically significant reduction in disease progression. Heavy selloff despite weak prior sentiment. Trades at discounted 13.6x 2026 consensus earnings, 3.7% yield reflects lowered expectations.
Read full article (1 min)